Yoichi Ozawa Selected Research

CREB-Binding Protein

1/2021

E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoichi Ozawa Research Topics

Disease

11	Neoplasms (Cancer) 01/2022 - 11/2002
4	Hypoxia (Hypoxemia) 01/2021 - 04/2012
2	Vascular Remodeling 01/2023 - 10/2014
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 04/2017
2	Neoplasm Metastasis (Metastasis) 12/2017 - 10/2014
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2021
1	Polyps 01/2021
1	Stomach Neoplasms (Stomach Cancer) 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 12/2018
1	Vascular Tissue Neoplasms 12/2017
1	Breast Neoplasms (Breast Cancer) 10/2014
1	Glioma (Gliomas) 04/2012
1	Colorectal Neoplasms (Colorectal Cancer) 11/2002

Drug/Important Bio-Agent (IBA)

4	lenvatinibIBA 01/2022 - 04/2017
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 10/2014
3	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2018
2	eribulin FDA Link 01/2023 - 10/2014
2	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 10/2014
2	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 12/2017 - 04/2017
2	Proteins (Proteins, Gene)FDA Link 10/2014 - 04/2012
1	AntibodiesIBA 01/2022
1	CREB-Binding ProteinIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	CateninsIBA 01/2021
1	NivolumabIBA 12/2018
1	Angiogenesis InhibitorsIBA 12/2018
1	Sorafenib (BAY 43-9006)FDA Link 12/2018
1	Liposomes (Liposome)IBA 12/2017
1	TOR Serine-Threonine KinasesIBA 04/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2017
1	Everolimus FDA Link 04/2017
1	TubulinIBA 10/2014
1	Capecitabine (Xeloda)FDA Link 10/2014
1	bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA 10/2014
1	Transcription Factors (Transcription Factor)IBA 10/2014
1	Irinotecan (Camptosar)FDA LinkGeneric 05/2012
1	SulfonamidesIBA 05/2012
1	N- (3- chloro- 7- indolyl)- 1,4- benzenedisulphonamide (E7070)IBA 05/2012
1	Hypoxia-Inducible Factor 1IBA 04/2012
1	ER-400583-00IBA 04/2012
1	N- (3- cyano- 4- methyl- 1H- indol- 7- yl)- 3- cyanobenzene- sulfonamideIBA 11/2002

Therapy/Procedure

3	Therapeutics 01/2022 - 12/2018
2	Oral Administration 04/2012 - 11/2002
1	Immunomodulation 01/2023
1	Immunotherapy 01/2019
1	Radiotherapy 04/2012